NCT01013506: Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer |
|
|
| Withdrawn | 2 | 0 | US | IGF-1R inhibitor OSI-906, erlotinib hydrochloride, Tarceva, goserelin, Zoladex, letrozole, Femara | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI) | Breast Cancer | 12/09 | 12/09 | | |
NCT01205685: Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer |
|
|
| Terminated | 2 | 11 | US | OSI-906, Erlotinib, Letrozole, Goserelin | Vanderbilt-Ingram Cancer Center | Hormone-sensitive Metastatic Breast Cancer | 07/11 | 07/11 | | |
